Mucosal Delivery and Retention of Ebola Inhibitor Scytovirin Using Lactobacillus

使用乳酸菌进行埃博拉抑制剂 Scytovirin 的粘膜递送和保留

• 批准号: 9318070
• 负责人: Shi-hua Xiang
• 金额: $ 19.19万
• 依托单位: UNIVERSITY OF NEBRASKA LINCOLN
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-28 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9318070
• 关键词: Affect; Africa; Bacteria; Binding; Carbohydrates; Cells; Cessation of life; Cyanobacterium; Cyanovirin-N; Developing Countries; Disease Outbreaks; Ebola virus; Engineered Gene; Engineering; Environment; Epidemic; Escherichia coli; Gene Expression; Genetic screening method; Glycoproteins; Goals; HIV-1; Human; Human body; In Vitro; Infection; Infection prevention; Lactobacillus; Lectin; Lectin Inhibitor; Molecular; Molecular Conformation; Pharmaceutical Preparations; Prevention; Property; Proteins; Research; Surface; System; Testing; Vaccines; Viral; Viral Hemorrhagic Fevers; Virus Diseases; base; combat; cost effective; disorder prevention; fight against; gene synthesis; in vivo; inhibitor/antagonist; lactic acid bacteria; mortality; mouse model; tissue culture; transmission process

Abstract A natural protein molecule, scytovirin (SVN) from cyanobacteria has been found to have a strong inhibitory activity against Ebola infection. This project will utilize the anti-viral property of scytovirin and in combination with lactic acid bacteria (LAB) to build up an anti-Ebola inhibitor mucosal delivery approach for the control of Ebola infection and transmission. This bacteria-based approach will be effective because the SVN inhibitor can be directly delivered at the mucosal surfaces right at the ports of viral entry. These anti-Ebola bacteria may not only be utilized for prevention, but also for treatment. Because the LAB can colonize in human body, a long- term efficacy could be achieved. This approach is also simple and cost-effective that can be easily used and managed in the regions of Ebola outbreaks and especially in the developing countries.

摘要 来自蓝藻的天然蛋白质分子scytovirin（SVN）已被发现具有强烈的抑制作用。 对抗埃博拉病毒感染。该项目将利用scytovirin的抗病毒特性， 与乳酸菌（LAB）建立一种抗埃博拉病毒抑制剂粘膜递送方法，用于控制 埃博拉病毒感染和传播。这种基于细菌的方法将是有效的，因为SVN抑制剂可以 直接在病毒进入口处的粘膜表面进行递送。这些抗埃博拉病毒的细菌 不仅用于预防，而且用于治疗。由于LAB可以在人体内定殖，长期- 可以达到长期疗效。这种方法也很简单，成本效益高，可以很容易地使用， 在埃博拉疫情爆发地区，特别是在发展中国家，